Aisling Capital is a leading investment firm that invests in companies developing and commercializing important and innovative healthcare products, services and technologies.

Meet Our Team

A combined 150+ years of experience in the healthcare industry.

learn more

See Our Portfolio

$1.8 billion in assets, with a track record of investing and returning capital since 2000.

learn more

Latest News

Aimmune Agrees to be Acquired by Nestlé Health Science

August 31, 2020
Sociétés des Produits Nestlé S.A., part of Nestlé Health Science, to acquire Aimmune for $34.50 per share in cash, representing a total equity value of $2.6 Billion and a 174% premium to Aimmune’s closing…

Harmony Biosciences Announces Closing of its Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

August 21, 2020
PLYMOUTH MEETING, PA and CHICAGO, IL, August 21, 2020 — Harmony Biosciences Holdings, Inc. (“Harmony”), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients living with rare neurological…

Zosano Pharma Announces Partnership Agreement with EVERSANA to Support the Launch and Commercialization of Qtrypta™

August 6, 2020
Agreement outlines commercialization and distribution execution strategy upon FDA approval EVERSANA to provide commercial services of approximately $250 million over 5 years FREMONT, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (NASDAQ:ZSAN), a clinical-stage…